Literature DB >> 26196846

Serum S100β Neuroprotein Reduces Use of Cranial Computed Tomography in Children After Minor Head Trauma.

Jeanne Simon-Pimmel1, Fleur Lorton, Nicolas Guiziou, Karine Levieux, Bénédicte Vrignaud, Damien Masson, Benoit Dupas, Christèle Gras-Leguen.   

Abstract

Minor head trauma is a common reason for consultation in pediatric emergency departments. In 2009, the Pediatric Emergency Care Applied Research Network (PECARN) published a clinical decision rule for its management. It aimed to help clinicians identify children with a very low risk of developing intracranial lesions, so that unnecessary cranial computed tomography (CCT) scan radiation could be avoided, as such exposure is associated with a rising risk of cancer in this young population. In the meantime, the serum S100β neuroprotein showed encouraging results, with a 30% potential decrease in CCTs for the management of minor head traumas in adults and children. The aim of this study was to determine if the serum S100β neuroprotein, associated with the PECARN clinical decision rule, could safely reduce the use of CCTs. We included children who were examined at the pediatric emergency department for minor head trauma, who underwent a CCT, whose blood samples were analyzed to determine the level of the serum S100β protein. They were managed according to the PECARN clinical decision rule. We afterward assessed the potential decrease in the number of CCTs, according to a modified PECARN clinicobiological decision rule, had we taken into account the result of the blood tests. One hundred nine children were included, and nine of them had clinically important traumatic brain injury. Four of them had a negative S100β value but were classified as high risk of developing intracranial lesion according to the PECARN clinical decision rule. Had we taken into account the modified PECARN clinicobiological decision rule, none of them would have been missed. However, there were 32 true negatives of the rule, allowing a potential decrease in CCTs rated at 29% (95% confidence interval, 21-38). Integrating the serum S100β neuroprotein assessment in the PECARN clinical decision rule could avoid deleterious exposure to CCT radiation, with the condition of using a clinicobiological rule to avoid missing clinically important traumatic brain injuries. Those results have yet to be confirmed relying on a large multicentric study.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26196846     DOI: 10.1097/SHK.0000000000000442

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  5 in total

1.  Validation of the Sainte-Justine Head Trauma Pathway for children younger than two years of age.

Authors:  Sarah Spénard; Sarah Gouin; Marianne Beaudin; Jocelyn Gravel
Journal:  Can J Surg       Date:  2018-08       Impact factor: 2.089

Review 2.  Biomarkers in Moderate to Severe Pediatric Traumatic Brain Injury: A Review of the Literature.

Authors:  Jennifer C Munoz Pareja; Xue Li; Nithya Gandham; Kevin K Wang
Journal:  Pediatr Neurol       Date:  2022-03-18       Impact factor: 3.372

Review 3.  Will mesenchymal stem cells be future directions for treating radiation-induced skin injury?

Authors:  Zhuoqun Fang; Penghong Chen; Shijie Tang; Aizhen Chen; Chaoyu Zhang; Guohao Peng; Ming Li; Xiaosong Chen
Journal:  Stem Cell Res Ther       Date:  2021-03-12       Impact factor: 6.832

4.  GFAP and S100B: What You Always Wanted to Know and Never Dared to Ask.

Authors:  Damir Janigro; Stefania Mondello; Jussi P Posti; Johan Unden
Journal:  Front Neurol       Date:  2022-03-21       Impact factor: 4.003

Review 5.  Traumatic brain injury biomarkers in pediatric patients: a systematic review.

Authors:  Lucas Alexandre Santos Marzano; Joao Pedro Thimotheo Batista; Marina de Abreu Arruda; Maíra Glória de Freitas Cardoso; João Luís Vieira Monteiro de Barros; Janaína Matos Moreira; Priscila Menezes Ferri Liu; Antônio Lúcio Teixeira; Ana Cristina Simões E Silva; Aline Silva de Miranda
Journal:  Neurosurg Rev       Date:  2021-06-25       Impact factor: 2.800

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.